Previous Page  14 / 76 Next Page
Information
Show Menu
Previous Page 14 / 76 Next Page
Page Background

NCCN Annual Report 2016

12

Oncology Research

Combination

Therapies Tested

in Groundbreaking

NCCN Research

In 2016, the NCCN Oncology Research Program (ORP) funded researchers at three

Member Institutions to study combination therapies containing afatinib in patients with

lung and head and neck cancers.

This was NCCN ORP’s first multi-industry collaborative research project in which

two pharmaceutical companies are collaborating with NCCN to study combination

therapeutic agents.

The following studies were awarded funding in this collaborative research project

through NCCN ORP:

Aarti Bhatia, MD, MPH, Yale Cancer Center/Smilow Cancer Hospital,

Single-

Arm Phase II Trial of Dual Inhibition of EGFR with Afatinib and Cetuximab with

Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic

Squamous Cell Cancers of the Head and Neck

Michael Gibson, MD, PhD, Case Comprehensive Cancer Center/University

Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute,

Afatinib and Nivolumab as Treatment of Platinum- and Cetuximab-Refractory

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Leora Horn, MD, Vanderbilt-Ingram Cancer Center,

Phase I Trial of Combination

Afatinib and Necitumumab in EGFR Mutation Positive NSCLC with Acquired

Resistance to First or Third Generation EGFR TKIs

>

For more information about NCCN ORP, visit

NCCN.org/ORP

.